Arnold R Gammaitoni

Summary

Affiliation: Endo Pharmaceuticals
Country: USA

Publications

  1. ncbi Pharmacokinetics and safety of continuously applied lidocaine patches 5%
    Arnold R Gammaitoni
    Endo Pharmaceuticals Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
    Am J Health Syst Pharm 59:2215-20. 2002
  2. ncbi Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain
    Bradley S Galer
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:S5-12. 2004
  3. ncbi Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:S13-9. 2004
  4. ncbi Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain
    Arnold R Gammaitoni
    Endo Pharmaceuticals Inc, Chadds Ford, Pennsylvania 19317, USA
    Pain Med 4:21-30. 2003
  5. ncbi Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing
    Arnold R Gammaitoni
    Endo Pharmaceuticals, 100 Painters Dr, Chadds Ford, PA 19317 9007, USA
    Ann Pharmacother 36:236-40. 2002
  6. ncbi Clinical application of opioid equianalgesic data
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, Chadds Ford, Pennsylvania 19317, USA
    Clin J Pain 19:286-97. 2003
  7. doi The pain quality response profile of oxymorphone extended release in the treatment of low back pain
    Errol M Gould
    Endo Pharmaceuticals Inc, Chadds Ford, PA 19317, USA
    Clin J Pain 25:116-22. 2009
  8. ncbi Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
    J Clin Pharmacol 43:296-304. 2003
  9. ncbi Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis
    Bradley S Galer
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:1455-8. 2004
  10. ncbi Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature
    Arnold R Gammaitoni
    Endo Pharmaceuticals, 100 Painters Drive, Chadds Ford, PA 19317, USA
    J Clin Pharmacol 43:111-7. 2003

Detail Information

Publications22

  1. ncbi Pharmacokinetics and safety of continuously applied lidocaine patches 5%
    Arnold R Gammaitoni
    Endo Pharmaceuticals Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
    Am J Health Syst Pharm 59:2215-20. 2002
    ..Mild application-site erythema occurred in most patients, but no systemic adverse reactions were judged to be related to the patches. No loss in sensation at the application site was reported...
  2. ncbi Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain
    Bradley S Galer
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:S5-12. 2004
    ..To determine the impact of the lidocaine patch 5% on pain qualities associated with low-back pain (LBP) through use of the Neuropathic Pain Scale (NPS)...
  3. ncbi Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:S13-9. 2004
    ..e.sharp, dull)...
  4. ncbi Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain
    Arnold R Gammaitoni
    Endo Pharmaceuticals Inc, Chadds Ford, Pennsylvania 19317, USA
    Pain Med 4:21-30. 2003
    ..5- and 10-mg/acetaminophen 325-mg (Percocet) formulations in patients with low back pain (LBP) suboptimally responsive to nonsteroidal anti-inflammatory drugs, muscle relaxants, tramadol, cyclo-oxygenase-2 inhibitors, and/or prn opioids...
  5. ncbi Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing
    Arnold R Gammaitoni
    Endo Pharmaceuticals, 100 Painters Dr, Chadds Ford, PA 19317 9007, USA
    Ann Pharmacother 36:236-40. 2002
    ..To assess the pharmacokinetics, safety, and tolerability of lidocaine delivered via 4 lidocaine 5% patches applied for 18 h/d for 3 consecutive days in healthy volunteers...
  6. ncbi Clinical application of opioid equianalgesic data
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, Chadds Ford, Pennsylvania 19317, USA
    Clin J Pain 19:286-97. 2003
    ..This approach may help to build a comfort level when dealing with the clinical challenges of converting from one opioid to another...
  7. doi The pain quality response profile of oxymorphone extended release in the treatment of low back pain
    Errol M Gould
    Endo Pharmaceuticals Inc, Chadds Ford, PA 19317, USA
    Clin J Pain 25:116-22. 2009
    ..This study sought to evaluate the utility of assessing the multiple components of non-neuropathic pain in an analgesic clinical trial...
  8. ncbi Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
    J Clin Pharmacol 43:296-304. 2003
    ..This new formulation offers the combination of two analgesic drugs with complementary mechanisms of action, which results in enhanced analgesia, an "opioid-sparing" effect, and an improved side effect and safety profile...
  9. ncbi Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis
    Bradley S Galer
    Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
    Curr Med Res Opin 20:1455-8. 2004
    ..Topical lidocaine patch 5% may provide clinicians with a novel, non-systemic therapy for OA pain with a unique mechanism of action...
  10. ncbi Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature
    Arnold R Gammaitoni
    Endo Pharmaceuticals, 100 Painters Drive, Chadds Ford, PA 19317, USA
    J Clin Pharmacol 43:111-7. 2003
    ..The lidocaine patch provides a treatment option that carries a relatively low systemic adverse event and drug-drug interaction risk burden, even with continuous application of up to four patches per day...
  11. ncbi Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations
    Arnold R Gammaitoni
    Endo Pharmaceuticals, Inc, Chadds Ford, Pennsylvania 19317, USA
    J Clin Pharmacol 42:192-7. 2002
    ..Increasing dose levels of oxycodone/acetaminophen provides proportional increases in oxycodone Cmax and AUC. Adverse events were predictable based on the opioid pharmacologic actions of this agent...
  12. doi The dimensions of pain quality: factor analysis of the Pain Quality Assessment Scale
    Timothy W Victor
    Endo Pharmaceuticals Inc, Chadds Ford, PA 19317, USA
    Clin J Pain 24:550-5. 2008
    ..To provide a better empirical understanding of the dimensionality of neuropathic and non-neuropathic pain quality...
  13. doi Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scale
    Arnold R Gammaitoni
    Global Center for Scientific Affairs, Merck Sharp and Dohme Corp, Whitehouse Station, New Jersey, USA
    Pain Med 14:526-32. 2013
    ..The aim of this study is to assess the Pain Quality Assessment Scale (PQAS) in predicting pregabalin in peripheral neuropathic pain (NP)...
  14. ncbi Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale
    Mark P Jensen
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Pain 6:98-106. 2005
    ..The results support the potential utility of the NPS for assessing the patterns of changes in pain qualities that can be observed after pain treatment...
  15. pmc A comparison of the lidocaine patch 5% vs naproxen 500 mg twice daily for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group study
    Srinivas Nalamachu
    Kansas City University of Medicine and Biosciences, Kansas City, Missouri, USA
    MedGenMed 8:33. 2006
    ..This pilot clinical trial was designed to compare the safety and effectiveness of the lidocaine patch 5% to that of naproxen 500 mg twice daily for the treatment of neuropathic pain associated with CTS...
  16. ncbi Effectiveness of lidocaine patch 5% in patients with or without allodynia
    Arnold R Gammaitoni
    CNS Spectr 11:906. 2006
  17. ncbi The pain quality assessment scale: assessment of pain quality in carpal tunnel syndrome
    Mark P Jensen
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    J Pain 7:823-32. 2006
    ..No significant differences were found between the 2 treatment conditions on any of the items. The results support the validity of the PQAS items for assessing the effects of pain treatment on pain qualities of carpal tunnel syndrome...
  18. ncbi Symptom profiles differ in patients with neuropathic versus non-neuropathic pain
    Robert H Dworkin
    Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Pain 8:118-26. 2007
    ....
  19. ncbi Do pain qualities and spatial characteristics make independent contributions to interference with physical and emotional functioning?
    Mark P Jensen
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, 98195 6490, USA
    J Pain 7:644-53. 2006
    ....
  20. ncbi Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale
    Charles E Argoff
    Cohn Pain Management Center, North Shore University Hospital NYU School of Medicine, Bethpage, NY 11714, USA
    Curr Med Res Opin 20:S21-8. 2004
    ..To determine the impact of the lidocaine patch 5% on pain qualities associated with chronic pain from postherpetic neuralgia (PHN), painful diabetic neuropathy (DN), and low-back pain (LBP), using the Neuropathic Pain Scale (NPS)...
  21. ncbi Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways
    Michael Adams
    SFBC New Drug Services Inc, Kennett Square, Pennsylvania, USA
    J Clin Pharmacol 45:337-45. 2005
    ..Oxymorphone ER exhibits a minimal potential for causing metabolic drug-drug interactions mediated by CYP2C9 or CYP3A4...
  22. ncbi More than 7 years of consistent neuropathic pain relief in geriatric patients
    Bradley S Galer
    Arch Intern Med 163:628. 2003